California’s decade-long legalization experience provides critical real-world data on how policy frameworks affect patient access to quality-controlled cannabis medicines. The persistence of illegal markets directly impacts patient safety through unregulated products and inconsistent dosing.
California’s 10-year legal cannabis market continues to compete with substantial illegal distribution networks, creating a dual-market environment that affects medical patients. Legal dispensaries offer lab-tested products with consistent potency and contaminant screening, while illegal sources may provide untested products at lower costs. This market fragmentation impacts patient access to reliable, pharmaceutical-grade cannabis medicines and creates challenges for clinical dosing consistency.
“The illegal market persistence tells us that regulatory frameworks still aren’t meeting patient needs for affordable, accessible cannabis medicine. When patients turn to unregulated sources, we lose clinical control over product quality and dosing reliability.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
